期刊文献+

乙型肝炎病毒变异及其临床意义 被引量:2

下载PDF
导出
摘要 人感染乙型肝炎病毒(HBV)可出现不同临床结局。患者可表现为急性自限性感染,也可表现为慢性HBV感染,部分患者出现慢性乙型肝炎(CHB),并可进展为肝炎肝硬化和肝细胞癌(HCC)。不同的临床结局是宿主因素与病毒因素共同作用的结果,其中病毒变异因素在患者的临床结局中起重要作用。HBV每24小时可复制约10^12~10^13个拷贝[11:患者血清HBV的半寿期为1~2d;由于HBV聚合酶缺乏校正机制,HBV的突变率为(1.4~3.2)X10-5核苷酸替代/(位点·年)^[2]。这些特点决定了HBV存在广泛的异质性。
作者 杨松 成军
出处 《诊断学理论与实践》 2009年第2期125-128,共4页 Journal of Diagnostics Concepts & Practice
基金 首都特色临床医学技术发展研究研发攻关类项目(Z07050700690702)
  • 相关文献

参考文献24

  • 1Nowak MA,Bonhoeffer S,Hill AM,et al.Viral dynamics in hepatitis B virus infection[J].Proc Natl Acad Sci USA,1996,93(9):4398-4402.
  • 2Wai CT,Fontana RJ.Clinical significance of hepatitis B virus genotypes,variants,and mutants[J].Clin Liver Dis,2004,8(2):321-352.
  • 3Stuyver LJ,Locarnini SA,Lok A,et al.Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region[J].Hepatology,2001,33(3):751-757.
  • 4Tong S.Mechanism of HBV genome variability and replication of HBV mutants[J].J Clin Virol,2005,34 (Suppl 1):S134-S138.
  • 5Chen CH,Lee CM,Hung CH,et al.Clinical significance and evolution of core promoter and precore mutations in HBeAg-pesitive patients with HBV genotype B and C:a longitudinal study[J].Liver Int,2007,27(6):806-815.
  • 6Fang ZL,Sabin CA,Dong BQ,et al.HBV AI762T,G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma:a prospective study[J].Am J Gastroenterol,2008,103(9):2254-2262.
  • 7Tanaka Y,Mukaide M,Orito E,et al.Specific mutations in enhancer Ⅱ/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma[J].J Hepatol,2006,45(5):646-653.
  • 8Buti M,Rodrignez-Frias F,Jardi R,et al.Hepatitis B virus genome variability and disease progression:the impact of pre-core mutants and HBV genotypes[J].J Clin Virol,2005,34 Suppl 1:S79-S82.
  • 9Frelin L,Wahlstrom T,Tucker AE,et al.A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection[J].J Virol,2009,83(3):1379-1392.
  • 10Imamura T,Yokosuka O,Kurihara T,et al.Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba,Japan[J].Gut,2003,52 (11):1630-1637.

二级参考文献23

  • 1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
  • 2[1]Allen MI,Gauthier J,DesLauriers M,et al.Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine.J Clin Microbiol,1999,37:3338-3347.
  • 3[3]Kim HS,Han KH,Ahn SH,et al.Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization.Antivir Ther,2005,10:441-449.
  • 4[4]Hussain M,Fung S,Libbrecht E,et al.Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.J Clin Microbiol,2006,44:1094-1097.
  • 5[5]Tran N,Berne R,Chann R,et al.European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes.J Clin Microbiol,2006,44:2792-2800.
  • 6[6]Jacquard AC,Brunelle MN,Pichoud C,et al.In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.Antimicrob Agents Chemother,2006,50:955-961.
  • 7[7]Delaney WE 4th,Edwards R,Colledge D,et al.Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.Antimicrob Agents Chemother,2001,45:1705-1713.
  • 8[8]Angus P,Vaughan R,Xiong S,et al.Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.Gastroenterology,2003,125:292-297.
  • 9[9]Yuen LK,Ayres A,Littlejohn M,et al.SeqHepB:a sequence analysis program and relational database system for chronic hepatitis B.Antiviral Res,2007,75:64-74.
  • 10[10]Bartholomeusz A,Locarnini SA.Antiviral drug resistance:clinical consequences and molecular aspects.Semin Liver Dis,2006,26:162-170.

共引文献39

同被引文献15

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部